nach oben

Drugs

Erschienen in:

01.06.2013 | Adis Drug Evaluation

Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias

verfasst von: Greg L. Plosker

Erschienen in: Drugs | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Landiolol (Onoact^®) is an intravenously administered, ultra short-acting β₁-blocker with an elimination half-life of 3–4 min and ≈8-fold greater cardioselectivity than esmolol in vitro. It is approved in Japan for the treatment of intraoperative and postoperative tachyarrhythmias, but in clinical practice is also used to prevent postoperative tachyarrhythmias, such as atrial fibrillation after coronary artery bypass grafting. Randomized controlled trials in patients undergoing open-heart surgery demonstrated that various dosages of landiolol (0.0005–0.04 mg/kg/min) [0.5–40 μg/kg/min] were more effective than diltiazem in converting postoperative atrial fibrillation to normal sinus rhythm during the first 8 h after surgery, and were more effective than placebo (or no landiolol) in preventing the development of atrial fibrillation during the first week after surgery (primary efficacy endpoints). In patients undergoing surgical procedures, landiolol 0.125 mg/kg/min for 1 min followed by 0.04 mg/kg/min for 10 min was superior to placebo in improving intraoperative tachycardia in randomized double-blind trials. The beneficial effects of landiolol in attenuating adverse haemodynamic or other changes that can occur during surgery or invasive procedures (e.g. percutaneous coronary intervention) have been demonstrated in a large number of randomized controlled trials. For example, several studies showed that landiolol attenuated the increase in heart rate associated with tracheal intubation, without adversely affecting blood pressure or other haemodynamic parameters. Landiolol was generally well tolerated in clinical trials, with a relatively low risk of hypotension and bradycardia, although routine monitoring of cardiac function during landiolol administration is important. In general, adverse events such as reduced blood pressure resolve quickly after discontinuation of landiolol. Thus, as an ultra short-acting β₁-blocker with a rapid onset of action and readily titratable and rapidly reversible effects, landiolol represents an important agent for the management of intraoperative and postoperative tachyarrhythmias.

Cardinale D, Martinoni A, Cipolla CM, et al. Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. Ann Thorac Surg. 1999;68(5):1827–31.CrossRefPubMed

Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation complicating lung cancer resection. J Thorac Cardiovasc Surg. 2005;130(2):438–44.CrossRefPubMed

Creswell LL, Schuessler RB, Rosenbloom M, et al. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56(3):539–49.CrossRefPubMed

Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94(3):390–7.CrossRefPubMed

Melduni RM, Koshino Y, Shen WK. Management of arrhythmias in the perioperative setting. Clin Geriatr Med. 2012;28(4):729–43.CrossRefPubMed

Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg. 1997;226(4):501–11 (discussion 11–3).

Vaporciyan AA, Correa AM, Rice DC, et al. Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg. 2004;127(3):779–86.CrossRefPubMed

Onoact (Onoakuto for injection, landiolol hydrochloride): Japanese prescribing information (revised April 2012); 2012. http://database.japic.or.jp/pdf/newPINS/00049024.pdf (Accessed 29 Apr 2013).

Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull. 1992;40(6):1462–9.CrossRefPubMed

10.

Yamakage M, Iwasaki S, Jeong S-W, et al. Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009;38(1):48–55.CrossRefPubMed

11.

Motomura S, Hagihara A, Narumi Y, et al. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol. 1998;31(3):431–40.CrossRefPubMed

12.

Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol. 1999;34(1):70–7.CrossRefPubMed

13.

Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β-blocking agent in healthy volunteers (in Japanese). Rinsho Iyaku. 1997;13:4823–50.

14.

Mizuno J, Yoshiya I, Yokoyama T, et al. Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia. Eur J Clin Pharmacol. 2007;63(3):243–52.CrossRefPubMed

15.

Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–6.CrossRefPubMed

16.

Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–65.CrossRefPubMed

17.

Frishman WH, Saunders E. β-adrenergic blockers. J Clin Hypertens. 2011;13(9):649–53.CrossRef

18.

Kimura-Kurosawa S, Kanaya N, Kamada N, et al. Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart. J Anesth. 2007;21(4):480–9.CrossRefPubMed

19.

Kurosawa S, Kanaya N, Niiyama Y, et al. Landiolol, esmolol and propranolol protect from ischemia/reperfusion injury in isolated guinea pig hearts. Can J Anaesth. 2003;50(5):489–94.CrossRefPubMed

20.

Zhao H, Sugawara T, Miura S, et al. Intrathecal landiolol inhibits nociception and spinal c-Fos expression in the mouse formalin test. Can J Anaesth. 2007;54(3):201–7.CrossRefPubMed

21.

Kurita T, Takata K, Morita K, et al. Lipophilic β-adrenoceptor antagonist propranolol increases the hypnotic and anti-nociceptive effects of isoflurane in a swine model. Br J Anaesth. 2008;100(6):841–5.CrossRefPubMed

22.

Tsunekawa K, Imawaka H, Yamamoto K, et al. Studies on the metabolic fate of ultra short acting β₁-blocker ONO-1101 (3): metabolism and protein binding (in Japanese). Xenobio Metab Dispos. 1997;12:31–41.

23.

Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β₁-blocking agent in healthy volunteers (in Japanese). J Clin Ther Med. 2000;16(10):1531–56.

24.

Honda N, Nakade S, Kasai H, et al. Population pharmacokinetics of landiolol hydrochloride in healthy subjects. Drug Metab Pharmacokinet. 2008;23(6):447–55.CrossRefPubMed

25.

Murakami M, Furuie H, Matsuguma K, et al. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting β₁-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20(5):337–44.CrossRefPubMed

26.

Matsumoto N, Aomori T, Kanamoto M, et al. Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. Biol Pharm Bull. 2012;35(10):1655–60.CrossRefPubMed

27.

Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143–50.CrossRefPubMed

28.

Takahata T, Yasui-Furukori N, Sakamoto J, et al. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting β₁-blocker. Drugs R D. 2005;6(6):385–94.CrossRefPubMed

29.

Inoue S, Abe R, Kawaguchi M, et al. Metoclopramide does not prolong duration of action of landiolol attenuating the hemodynamic response to induction of anesthesia and tracheal intubation. J Anesth. 2010;24(4):649–52.CrossRefPubMed

30.

Suzuki T, Aono M, Isaka T, et al. Effect of landiolol hydrochloride on suxamethonium-induced neuromuscular block. J Anesth. 2009;23(2):188–91.CrossRefPubMed

31.

Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141(6):1478–87.CrossRefPubMed

32.

Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144(5):1241–8.CrossRefPubMed

33.

Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J. 2012;76(5):1097–101.CrossRefPubMed

34.

Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2012;53(3):369–74.

35.

Osada H, Nakajima H, Masuyama S, et al. Landiolol hydrochloride: prevention of atrial fibrillation after open-heart surgery (abstract no. P606). Eur Heart J. 2012;33:65.

36.

Nagaoka E, Arai H, Tamura K, et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2013; doi:10.5761/atcs.oa.12.02003.PubMed

37.

Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53(6):359–63.PubMed

38.

Ito N, Tashiro T, Morishige N, et al. Safety and efficacy of an ultrashort-acting β₁-blocker on left ventricular dysfunction. Heart Surg Forum. 2012;15(4):E189–94.CrossRefPubMed

39.

Tanaka K. Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):175–9 (discussion 9–83).

40.

Fujiwara H, Sakurai M, Namai A, et al. Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. 2009;57(3):132–7.CrossRefPubMed

41.

Yoshida Y, Terajima K, Sato C, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22(1):64–9.CrossRefPubMed

42.

To K, Iseki S, Setoguchi H. Landiolol hydrochloride improves the surgical Apgar score and outcome in off-pump coronary artery bypass surgery (abstract no. 700.00). Br J Anaesth. 2012;108:ii238.

43.

Wakamatsu H, Yokoyama H. Intraoperative infusion of landiolol hydrochloride, an ultra-short acting beta-1 adrenergic receptor blocker, prevents postoperative atrial fibrillation after off-pump coronary artery bypass surgery (abstract). Chest. 2011;140(4 Meeting Abstracts):508A.

44.

Uehara K, Ueyama K, Ito H, et al. Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone? (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):188–91.

45.

Ito S, Konishi T, Imazuru T, et al. Comparative study between landiolol and amiodarone for therapeutic efficacy after open heart surgery (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2011;64(13):1141–4.

46.

Nakanishi K, Takeda S, Kim C, et al. Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. J Cardiothorac Surg. 2013;8:19.CrossRefPubMed

47.

Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:4949–78.

48.

Yoshiya I, Ogawa R, Yasuhiro S. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia in patients with hypertension or cardiac ischemia: double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2002;18(9):1049–76.

49.

Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of an ultra short acting beta-1-blocker landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a double-blind, dose finding study (late phase II study) (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2000;16(10):1557–77.

50.

Tanaka N, Watanabe T, Mishima T, et al. Prevention of atrial fibrillation recurrence with low-dose landiolol administration after radiofrequency catheter ablation (abstract). J Cardiovasc Electrophysiol. 2011;22:S109.

51.

Nojiri T, Yamamoto K, Maeda H, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011;59(12):799–805.CrossRefPubMed

52.

Wariishi S, Yamashita K, Nishimori H, et al. Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. Interact Cardiovasc Thorac Surg. 2009;9(5):811–3.CrossRefPubMed

53.

Nakano T, Shimizu K, Kawashima O, et al. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther. 2012;37(4):431–5.CrossRefPubMed

54.

Uratsuji Y, Ijichi K, Irie J, et al. Effect of landiolol hydrochloride (ONO-1101) infusion on perioperative supraventricular tachyarrhythmia in several times (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:5009–26.

55.

Ishigaki D, Arimoto T, Iwayama T, et al. Landiolol, an ultrashort-acting β-blocker, for prevention of atrial fibrillation after catheter ablation (abstract no. P2374). Eur Heart J. 2012;33:352.

56.

Koyanagi K, Seishima R, Tabuchi S, et al. Usefulness of short-acting β₁ selective blocker (landiolol hydrochloride) for postoperative tachyarrhythmia after radical operation of esophageal cancer (abstract). Dis Esophagus. 2010;23:114A–5A.

57.

Okita T, Uji M, Shinjo T, et al. Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection (in Japanese). Jpn J Anesthesiol. 2008;57(8):953–8.

58.

Sugimoto R, Nakayama Y, Nawa Y. Administration of landiolol decreases the incidence of atrial fibrillation after lung lobectomy (abstract no. A1141). Annual Meeting of the American Society of Anesthesiologists, San Diego;2010.

59.

Taenaka N, Amaha K. Dose-dependent effect of landiolol, a new ultra-short-acting β₁-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013; doi:10.1007/s40261-013-0093x.

60.

Kawaguchi M, Utada K, Yoshitani K, et al. Effects of a short-acting β₁-receptor antagonist landiolol on hemodynamics and tissue injury markers in patients with subarachnoid hemorrhage undergoing intracranial aneurysm surgery. J Neurosurg Anesthesiol. 2010;22(3):230–9.CrossRefPubMed

61.

Harasawa R, Hayashi Y, Iwasaki M, et al. Bolus administration of landiolol, a short-acting, selective β₁-blocker, to treat tachycardia during anesthesia: a dose-dependent study. J Cardiothorac Vasc Anesth. 2006;20(6):793–5.CrossRefPubMed

62.

Fox EJ, Sklar GS, Hill CH, et al. Complications related to the pressor response to endotracheal intubation. Anesthesiology. 1977;47(6):524–5.CrossRefPubMed

63.

Forbes AM, Dally FG. Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth. 1970;42(7):618–24.CrossRefPubMed

64.

Tanabe T, Fukusaki M, Fujinaga A, et al. Landiolol, a new ultra-short-acting β₁-blocker, reduces anaesthetic requirement during sevoflurane/N₂O/fentanyl anaesthesia in surgical patients. Eur J Anaesthesiol. 2009;26(1):39–42.CrossRefPubMed

65.

Kitamura A, Sakamoto A, Inoue T, et al. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol. 1997;51(6):467–71.CrossRefPubMed

66.

Yamazaki A, Kinoshita H, Shimogai M, et al. Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure. Can J Anaesth. 2005;52(3):254–7.CrossRefPubMed

67.

Ishikawa K, Shirakawa K, Nagao M, et al. Comparison of remifentanil and landiolol on hemodynamic and plasma catecholamine responses to tracheal intubation. Dokkyo J Med Sci. 2012;39(1):1–8.

68.

Kadoi Y, Horiuchi T, Uchida S, et al. Adequacy of control of preoperative hypertension can affect landiolol-induced hemodynamic changes in elderly patients during emergence from anesthesia. J Anesth. 2011;25(2):271–7.CrossRefPubMed

69.

Kawaguchi M, Kawaraguchi Y, Yamamoto Y, et al. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. J Anesth. 2010;24(4):503–10.CrossRefPubMed

70.

Miyazaki M, Kadoi Y, Saito S. Effects of landiolol, a short-acting β₁-blocker, on hemodynamic variables during emergence from anesthesia and tracheal extubation in elderly patients with and without hypertension. J Anesth. 2009;23(4):483–8.CrossRefPubMed

71.

Shirasaka T, Iwasaki T, Hosokawa N, et al. Effects of landiolol on the cardiovascular response during tracheal extubation. J Anesth. 2008;22(3):322–5.CrossRefPubMed

72.

Suehiro K, Okutani R. Landiolol attenuates cardiovascular response at induction of general anesthesia for cesarean delivery. J Anesth. 2012;26(2):200–5.CrossRefPubMed

73.

Oda Y, Nishikawa K, Hase I, et al. The short-acting β₁-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. Anesth Analg. 2005;100(3):733–7.CrossRefPubMed

74.

Sugiura S, Seki S, Hidaka K, et al. The hemodynamic effects of landiolol, an ultra-short-acting β₁-selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg. 2007;104(1):124–9.CrossRefPubMed

75.

Kawaguchi M, Takamatsu I, Masui K, et al. Effect of landiolol on bispectral index and spectral entropy responses to tracheal intubation during propofol anaesthesia. Br J Anaesth. 2008;101(2):273–8.CrossRefPubMed

76.

Goyagi T, Tanaka M, Nishikawa T. Landiolol attenuates the cardiovascular response to tracheal intubation. J Anesth. 2005;19(4):282–6.CrossRefPubMed

77.

Hirata N, Miyashita R, Watanabe A, et al. Low-dose continuous infusion of landiolol can reduce adrenergic response during tracheal intubation in elderly patients with cardiovascular disease. J Anesth. 2010;24(5):786–8.CrossRefPubMed

78.

Hirota K, Baba S, Fukushi S, et al. Efficacy of landiolol in attenuating hemodynamic responses to local epinephrine infiltration in patients undergoing vaginal total hysterectomy. J Anesth. 2005;19(1):17–20.CrossRefPubMed

79.

Horiuchi T, Uchida S, Kadoi Y, et al. Landiolol infusion attenuates increase in heart rate, but does not prevent increase in blood pressure in response to emergence from anesthesia and tracheal extubation (in Japanese). Jpn J Anesthesiol. 2010;59(9):1178–84.

80.

Onaka M, Yamamoto H. Effects of continuous infusion of landiolol on the hemodynamic response to tracheal intubation (in Japanese). Jpn J Anesthesiol. 2006;55(2):174–8.

81.

Kawano T, Eguchi S, Iseki A, et al. Effects of landiolol on cardiovascular responses, bispectral index and body movement during endotracheal intubation (in Japanese). Jpn J Anesthesiol. 2005;54(6):610–4.

82.

Tachikawa M, Shimazaki M, Arai T, et al. Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting [in Japanese]. Jpn J Anesthesiol. 2012;61(6):566–73.

83.

Nishiyama Y. The effect of landiolol on bispectral index scores in patients undergoing lower abdominal surgery (in Japanese). Jpn J Anesthesiol. 2012;61(2):217–20.

84.

Goto K, Shingu C, Miyamoto S, et al. The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. J Clin Anesth. 2007;19(7):523–9.CrossRefPubMed

85.

Miyazaki M, Kadoi Y, Takashi S, et al. Comparative effects of propofol, landiolol, and nicardipine on hemodynamic and bispectral index responses to endotracheal intubation: a prospective, randomized, double-blinded study. J Clin Anesth. 2008;20(4):257–62.CrossRefPubMed

86.

Kaneko M, Yamaguchi S, Hamaguchi S, et al. Effects of landiolol on QT interval and QT dispersion during induction of anesthesia using computerized measurement. J Clin Anesth. 2009;21(8):555–61.CrossRefPubMed

87.

Inoue S, Tanaka Y, Kawaguchi M, et al. The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review. Anaesth Intensive Care. 2009;37(6):893–902.PubMed

88.

Nonaka A, Suzuki S, Abe F. The effects of continuous infusion of landiolol on heart rate changes after neostigmine-atropine administration during recovery from general anesthesia (in Japanese). Jpn J Anesthesiol. 2006;55(12):1459–62.

89.

Wajima Z, Tsuchida H, Shiga T, et al. Intravenous landiolol, a novel β₁-adrenergic blocker, reduces the minimum alveolar concentration of sevoflurane in women. J Clin Anesth. 2011;23(4):292–6.CrossRefPubMed

90.

Takizawa D, Saito S, Sato E, et al. Influence of landiolol on the dose requirement of propofol for induction of anesthesia. Fundam Clin Pharmacol. 2005;19(5):597–9.CrossRefPubMed

91.

Goto K, Hagiwara S, Hidaka S, et al. The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery. J Anesth. 2010;24(1):11–6.CrossRefPubMed

92.

Matsura M, Fujiwara Y, Ito H, et al. Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol. J ECT. 2010;26(1):37–40.CrossRefPubMed

93.

Nomoto K, Suzuki T, Serada K, et al. Effects of landiolol on hemodynamic response and seizure duration during electroconvulsive therapy. J Anesth. 2006;20(3):183–7.CrossRefPubMed

94.

Sakamoto A, Ogawa R, Suzuki H, et al. Landiolol attenuates acute hemodynamic responses but does not reduce seizure duration during maintenance electroconvulsive therapy. Psychiatry Clin Neurosci. 2004;58(6):630–5.CrossRefPubMed

95.

Saito S, Nishihara F, Akihiro T, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52(10):1027–34.CrossRefPubMed

96.

Ide M, Kadoi Y, Saito S, et al. Effects of landiolol on left ventricular function during electroconvulsive therapy: a transthoracic echocardiographic study. J Anesth. 2010;24(2):272–6.CrossRefPubMed

97.

Wajima Z, Shiga T, Imanaga K, et al. Prophylactic continuous administration of landiolol, a novel β₁ blocker, blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity. Int J Psych Clin Pract. 2010;14(2):132–6.CrossRef

98.

Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2012; doi:10.1016/j.ijcard.2012.04.096.

99.

Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–45.CrossRefPubMed

100.

Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–6.CrossRefPubMed

101.

Higuchi H. Feasibility of continuous intravenous administration of landiolol for acute myocardial infarction: first clinical experience and its safe directions for use (abstract no. E953). J Am Coll Cardiol. 2010;55(10 Suppl):A102.

102.

Morita H, Kono T, Suzuki S, et al. Intravenous administration of subdepressor dose of short-acting beta-blocker landiolol before percutaneous coronary intervention may reduce the incidence of myocardial infarction in stable angina (abstract no. 1041-157). J Am Coll Cardiol. 2009:A342.

103.

Mitchell LB. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol. 2011;27(1):91–7.CrossRefPubMed

104.

Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30(22):2769–812.CrossRefPubMed

105.

Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(10):e269–367.CrossRefPubMed

106.

Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias - executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493–531.CrossRefPubMed

107.

Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72(1):109–32.CrossRefPubMed

Titel: Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias
verfasst von: Greg L. Plosker
Publikationsdatum: 01.06.2013
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 9/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-013-0077-4

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2013

Loteprednol Etabonate Ophthalmic Gel 0.5 %: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery

Teduglutide: A Review of its Use in the Treatment of Patients with Short Bowel Syndrome

HIV-Associated Neurocognitive Disorders: Perspective on Management Strategies

Canagliflozin: First Global Approval

New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy

Metreleptin: First Global Approval